JP2024503249A5 - - Google Patents
Info
- Publication number
- JP2024503249A5 JP2024503249A5 JP2023537550A JP2023537550A JP2024503249A5 JP 2024503249 A5 JP2024503249 A5 JP 2024503249A5 JP 2023537550 A JP2023537550 A JP 2023537550A JP 2023537550 A JP2023537550 A JP 2023537550A JP 2024503249 A5 JP2024503249 A5 JP 2024503249A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063128391P | 2020-12-21 | 2020-12-21 | |
| US63/128,391 | 2020-12-21 | ||
| PCT/US2021/063771 WO2022140150A1 (en) | 2020-12-21 | 2021-12-16 | Compositions and methods for site-directed mutagenesis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024503249A JP2024503249A (ja) | 2024-01-25 |
| JP2024503249A5 true JP2024503249A5 (https=) | 2024-12-23 |
| JPWO2022140150A5 JPWO2022140150A5 (https=) | 2024-12-23 |
Family
ID=82158380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537550A Pending JP2024503249A (ja) | 2020-12-21 | 2021-12-16 | 部位特異的変異導入のための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240336904A1 (https=) |
| EP (1) | EP4262850A4 (https=) |
| JP (1) | JP2024503249A (https=) |
| KR (1) | KR20230122628A (https=) |
| CN (1) | CN116887853A (https=) |
| AU (1) | AU2021410632A1 (https=) |
| CA (1) | CA3202889A1 (https=) |
| WO (1) | WO2022140150A1 (https=) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012118717A2 (en) * | 2011-02-28 | 2012-09-07 | Seattle Children's Research Institute | Coupling endonucleases with end-processing enzymes drive high efficiency gene disruption |
| RU2650811C2 (ru) * | 2012-02-24 | 2018-04-17 | Фред Хатчинсон Кэнсер Рисерч Сентер | Композиции и способы лечения гемоглобинопатии |
| US10000746B2 (en) * | 2013-05-31 | 2018-06-19 | Cellectis | LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof |
| US20180119174A1 (en) * | 2015-05-13 | 2018-05-03 | Seattle Children's Hospita (dba Seattle Children's Research Institute | Enhancing endonuclease based gene editing in primary cells |
| MX2018010924A (es) * | 2016-03-11 | 2019-02-13 | Bluebird Bio Inc | Células efectoras inmunitarias con edición genómica. |
| WO2018071565A1 (en) * | 2016-10-11 | 2018-04-19 | Bluebird Bio, Inc. | TCRa HOMING ENDONUCLEASE VARIANTS |
| IL313037A (en) * | 2017-05-25 | 2024-07-01 | 2Seventy Bio Inc | Cblb endonuclease variants, compositions, and methods of use |
| CN112533627A (zh) * | 2018-03-27 | 2021-03-19 | G+Flas 生命科学公司 | 序列特异性体内细胞靶向 |
| WO2020072059A1 (en) * | 2018-10-04 | 2020-04-09 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
| WO2020123371A2 (en) * | 2018-12-10 | 2020-06-18 | Bluebird Bio, Inc. | Homing endonuclease variants |
| US20220280567A1 (en) * | 2019-06-14 | 2022-09-08 | 2Seventy Bio, Inc. | Compositions and methods for treating cancer |
-
2021
- 2021-12-16 US US18/258,021 patent/US20240336904A1/en active Pending
- 2021-12-16 KR KR1020237024378A patent/KR20230122628A/ko active Pending
- 2021-12-16 WO PCT/US2021/063771 patent/WO2022140150A1/en not_active Ceased
- 2021-12-16 AU AU2021410632A patent/AU2021410632A1/en not_active Abandoned
- 2021-12-16 CA CA3202889A patent/CA3202889A1/en active Pending
- 2021-12-16 CN CN202180093810.4A patent/CN116887853A/zh active Pending
- 2021-12-16 EP EP21911917.9A patent/EP4262850A4/en active Pending
- 2021-12-16 JP JP2023537550A patent/JP2024503249A/ja active Pending